Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Guardant Health (GH) stock in plain English

Free brief · no signupStart here
GHPublished Nov 18, 2026
Guardant Health Inc
Healthcare · Diagnostics & Research
Sells blood-based cancer tests to oncologists, researchers, and pharmaceutical companies for clinical profiling and recurrence monitoring.
Assets:
Palo Alto laboratoryCLIA-certified and CAP-accredited high-throughput sequencing facility
Shield testFDA-approved blood screening assay for colorectal cancer
Guardant360 portfolioLiquid biopsy profiling platform used by oncologists and drug developers
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

60
OPS ScoreOperating finances
Latest quote
+0.31%$145.59
$19.70B
n/a (loss)
$1.28B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 18, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was GH. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Guardant Health (GH) do?

Guardant Health Inc (GH) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Sells blood-based cancer tests to oncologists, researchers, and pharmaceutical companies for clinical profiling and recurrence monitoring. Processes blood samples to detect cancer DNA, helping doctors select therapies and screen for recurrence without. It is worth $19.70B on the market and sold $1.28B over the last year.

Market cap
$19.70B
P/E ratio
None (reported a loss)
Annual sales
$1.28B
Sector
Healthcare
Industry
Diagnostics & Research
Brief updated
Nov 18, 2026

Brands and businesses behind GH

  • Guardant360: A blood test providing comprehensive genomic profiling for advanced cancer patients to guide targeted therapy decisions.
  • Shield: An FDA-approved blood test that screens average-risk adults for colorectal cancer during routine health checkups.
  • Guardant Reveal: A blood test detecting minimal residual disease to monitor early-stage cancer recurrence risks after surgery.

GH’s flags, in plain English

Each flag is a number from Guardant Health’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.

Still Climbing

Sales up 27.9% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Stupid Cash

Can pay this year's bills 3.6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Wide Gross Margin

Gross margin of 65.2% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Burning Cash

Losing money, profit margin of -37.9%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

Questions about GH

How big is Guardant Health?

Guardant Health’s market cap is $19.70B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $1.28B: what customers paid the company over the last year, before any costs.

What is GH’s P/E ratio?

GH has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with GH?

The business remains unprofitable and continues to spend substantial cash on clinical studies and commercial expansion. That is one risk on Guardant Health’s card. Its first risk flag is Burning Cash, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Guardant Health’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. GH’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card